Novartis' blood pressure Diovan is on the wane as its expects generics next quarter to begin eating at its blockbuster status. But even as it comes under attack by generics, so does its reputation, as…
According to an analysis by Bloomberg, Novartis is interested in finding a competitive Alzheimer's drug program. But it's hard to determine from the story if the pharma giant--always reluctant to deta…
* Novartis' one-third stake in Roche built up under Vasella…
ZURICH (Reuters) - Novartis has no plans to bid for U.S.-based generic drugmaker Actavis, which is the subject of intense takeover speculation, a spokesman for the Swiss drugmaker said on Thursday.
